Operational Highlights
- Revenues stood at ₹191.4 Cr in Q3FY22 from ₹183 Cr in Q3FY21 translating a growth of 4.6%
- EBITDA stood at ₹62.6 Cr with EBITDA margins at 31.5%
- PAT stood at ₹43.4 Cr with PAT margins at 22.6%
- 9MFY22 revenue split stood- Technicals + API: 72%, Formulations: 28%
- Profitability growth momentum continued backed by efficient business operations and unique product offerings.
- During the quarter, launched one product which received overwhelming response
- Presently have five upcoming products in pipeline and about to be launched by Q2FY 22-23
- Customers absorbed the incremental cost of high input prices
- Adama is major international competitor in fungicides
- 40-45% revenues from 3 key products i.e Captan, Folpet and Thiocarbamate
- Herbicides and Fungicides are distinctly separated to avoid any contamination
- Only in B2B business for export
- Already started technical registration process to get along parallel with EC.
- Will start manufacturing intermediates first and then as registration approves, it will be manufactured simultaneously
Capex
- Further increased our Sandila plant capacity by 500MT for new herbicide
- Progress of the ongoing expansion projects is as per timelines
- In process of environmental application for unit 3, TOR is expected in a month
- 2-3 quarters are required for capacity ramp up